Oral Medication Approved for MS in Canada

.

Oral Medication Approved for MS in Canada

Multiple Sclerosis treatment is bound to revolutionize in Canada as drug-maker Novartis Pharmaceutical Canada Inc. announced on Thursday that the first oral medicine for the condition has been approved for use by some patients in the country. The medication will basically help in providing treatment for the symptoms of MS.

The medicine has been named Gilenya and will be available for sale from the 1st of April at pharmaceutical stores across the nation. The medicine will be available for people who have tried another treatment for the condition with poor results.

The chemical name for Gilenya is fingolimod and it will be used for people with the relapsing-remitting form of the condition. According to the figures available, the disease ends up affecting an astounding 75,000 Canadians. People with this variety of the condition are likely to experience new symptoms with severity of older symptoms worsening.

Gilenya will help in reducing flare-ups of people suffering from multiple sclerosis and will also help in reducing the rate of progress. Each capsule of Gilenya contains 0.5 milligrams of the drug and is the most convenient treatment for MS in Canada.

Talking about the development, a Neurologist from Toronto, Dr. Daniel Selchan, said: "The approval of Gilenya is a significant milestone for the Canadian MS community".


Latest News

Good News for the Diabetic: FDA Approved Mobile Medical Application for Sharing
Fifth Death Related to Flu in Bay Area; The  First in Napa County
Ship Industry
For Bill Erbey Its Time to Pay Back
Union Organizers Files Lawsuit Against American Airlines
Venus In Past Had Vast Oceans of Liquid Carbon Dioxide, Say Researchers
Bill and Melinda Gates Have Long term Charity Plans but Now It’s Time for Super
Wynn Everett Casino Design Have Alterations with More luxury rooms and Lesser Pa
Alert Issued after Adult Film Actor became infected with HIV
Out Look for Oil Future Remains Weak Though Brent Crude Moves Above $48
BOJ Trimmed Its Inflation Forecast and Expanded Loan Scheme Aimed at Boosting Le
Layoff Reports at DreamWorks Animation following Changes in Higher Management Le